Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 9/20 | 1.00 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828290 | 1.00 | CFTR (1.00) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL30570546 | 0.87 | CFTR (0.77) | CFTRBAZ2BUSP2MAPTACHE | |
| SCHEMBL23828230 | 0.87 | CFTR (0.77) | CFTRBAZ2BUSP2MAPTACHE | |
| SCHEMBL23828229 | 0.82 | CFTR (0.70) | CFTRBAZ2BUSP2CYP1A2CYP2D6 | |
| SCHEMBL29171356 | 0.81 | BAZ2B (0.82) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL23828304 | 0.79 | CFTR (0.66) | CFTRBAZ2BKDRKDM4EMAPT | |
| SCHEMBL23828254 | 0.78 | CFTR (0.75) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL12868564 | 0.77 | LMNA (0.78) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL17447456 | 0.77 | BAZ2B (0.76) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL23828253 | 0.77 | CFTR (1.00) | CFTRBAZ2BKDRUSP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820867-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-09-13 | — | — | EP | claimed |
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | CFTR 1/4885BAZ2B 4498/4885KDR 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.